Both all-cause and ALD-related resource use and costs (defined as the Medicaid paid amount) were assessed in the follow-up period, including hospitalizations and hospital days, outpatient services, pharmacy prescriptions (analyzed for all-cause resource use and costs only), and other resource use (including nursing home stays, home health, hospice, and other services).
To investigate the impact of health literacy on VHA utilization (i.e., composed of: inpatient, outpatient and/or pharmacy), we analyzed data for patients who had utilization of services in each of the three years, for a final study population of 92,749.
Data from adults with RA with pharmacy claims for etanercept or adalimumab between 1/1/2007 and 12/31/2009 and continuous enrollment for ≥6 months before and ≥12 months after first (index) pharmacy claim were analyzed.
A retrospective cohort study of 17,988 new alendronate or risedronate users (age, ≥40 years) analyzed pharmacy and medical claims data from 45 large US employers (Briesacher et al 2007).
All antihypertensive drug prescription records from ambulatory care claims and prescriptions dispensed at contracted pharmacies were retrieved and analyzed for our sample of newly-diagnosed patients aged ≥30 years.
We analyzed a pharmacy benefit manager database to estimate claims-based, algorithm-determined effectiveness and cost per effectively treated patient for biologics used to treat RA.
This retrospective cohort study analyzed US pharmacy and medical claims data from the Thomson Reuters (Truven Health MarketScan® Commerciall and Medicare supplemental claims databases.
Aubert et al. (abstract 501) analyzed a pharmacy and medical claims database of 13 million persons, with information on 69,047 persons receiving a thiazolidinedione and 75,352 comparators, taking metformin, exenatide or a sulfonylurea.
We analyzed faxed pharmacy communications spanning from September to November 2011 (the period immediately prior to the implementation of the EMR) and we analyzed communications from one of the provincially approved EMRs (QHR Accuro) from September to November 2014 (39 months after EMR implementation).
J. Pharmaceutics, we analyze the future of pharmacy preparations (also known as extemporaneous preparations or compounded products).
